John Gram - Founder
Background: Over the years, John Gram has led the Oncology strategic decision support teams at Amgen, Biogen Idec, and Ligand Pharmaceuticals. He has also served as Vice-President, Marketing and Business Development at Novavax, a development stage cancer and women’s healthcare company, and was Executive Director, Corporate Development at SkinMedica, a specialty pharma company. After founding J.T. Gram & Associates, Inc. in 2003, John established long-term consulting engagements with the world’s largest CRO and health services organization, and a top-five Biotech company. Subsequent assignments have spanned scientific, strategic, and commercial assessments of oncology and rare disorder assets for large, small and mid-sized biopharmaceutical clients in support of business development and licensing activities, and new products commercialization.
Education: Executive Healthcare Program, Tuck School of Business, Dartmouth College;
Background: Board certified medical oncologist with over 30 years of drug development experience, over 20 years in industry. Lead role in six approved NDAs and BLAs with multiple successful submissions to European and Japanese agencies. He has presented at FDA Oncology Division Advisory Committee (ODAC) Meetings. He has been a critical contributor to numerous clinical reports and manuscripts and authored CPMP (Europe) Clinical Expert Reports. Successfully developed registration strategies for products in the U.S. and EU and has designed and conducted clinical protocols for Phase I-IV programs.
Education: Medical Degree at the New Jersey College of Medicine, Oncology training as National Cancer Institute Fellow at the Baltimore Cancer Research Center
New Products Marketing
Background: Over 20 years experience in the healthcare and pharmaceutical industry with experience spanning multiple therapeutic areas including Oncology, cardiovascular, infectious diseases, biologicals & vaccines, dermatology, inflammation and ophthalmology. Big Pharma background. Registered Nurse Practitioner, Pediatric Neurology/Oncology.
Education: Masters of Science degree from the University of Pennsylvania and a Masters in Business Administration from the Wharton School of Business.
Ph.D. Research Scientist
Background: Management executive with 19 years of experience in cutting-edge research and small molecule drug discovery, 14 years in the biotech industry. Most recently served as Head of Oncology overseeing preclinical drug discovery programs, target selection and validation, development of in vitro and cellular assays and in vivo tumor models. Proven track record of discovering drug candidates and advancing them to the clinical development stage. Introduced novel assays and model systems, brought in state-of-the art technology and cutting edge research approaches. Streamlined flow chart processes and increased standards, which overall increased the quality of the drug discovery pipeline and reduced lead time.
Education: Ph.D. University of Karlsruhe, Germany. Post-doctoral training at Duke Medical Center and UNC Chapel Hill Lineberger Comprehensive Cancer Center.